Ocumension Therapeutics (HKG:1477) reported 132.3 million yuan in loss for the first half of 2025, narrowing from a loss of 151.3 million yuan a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 0.17 yuan, compared with 0.23 yuan in the prior year.
Revenue at the drug company increased 75% year-on-year to 294 million yuan, figures showed.
Meanwhile, in a separate announcement, the company said its OT-301 drug candidate met the main goal of a second late-stage study.
The drug was found to be non-inferior to the current standard of care latanoprost in the phase 3 Denali trial of subjects with an eye condition called pen-angle glaucoma or ocular hypertension.
As a result, the medicine now meets the requirements for new drug approval in China, the firm said.
Ocumension Therapeutics is developing OT-301, also known as NCX 470, with Nicox.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。